ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
14 nov. 2024 08h10 HE
|
ZyVersa Therapeutics
ZyVersa announces progress toward achieving key near-term development milestones and Q3-2024 financials.
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes
05 nov. 2024 07h00 HE
|
ZyVersa Therapeutics
Inflammasome-driven inflammation in obesity results in severely damaged pancreatic islets, leading to islet cell loss and metabolic dysfunction.
ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs
29 oct. 2024 07h57 HE
|
ZyVersa Therapeutics
Obesity treatment needs to go beyond weight loss and address the damaging inflammation leading to life-altering comorbidities.
ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases
22 oct. 2024 07h57 HE
|
ZyVersa Therapeutics
Newly published data show that obesity leads to progressive brain inflammation that worsens with prolonged obesity and increased age.
ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors
15 oct. 2024 07h50 HE
|
ZyVersa Therapeutics
ZyVersa discusses trend toward add-on therapy for obesity to address metabolic complications and the role of inflammasome inhibitors on Big Biz Show.
ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications
07 oct. 2024 07h55 HE
|
ZyVersa Therapeutics
ZyVersa Therapeutics forms new obesity, metabolic and inflammatory disease Scientific Advisory Board.
ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults
29 juil. 2024 07h45 HE
|
ZyVersa Therapeutics
Plasma levels of inflammasome ASC show promise as a biomarker of early cognitive decline in older adults.
ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100
25 juil. 2024 07h57 HE
|
ZyVersa Therapeutics
WESTON, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...
ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model
18 juil. 2024 11h18 HE
|
ZyVersa Therapeutics
Inflammasome ASC Inhibitor IC 100 Reduced Inflammation and Restored Retinal Structure and Function in Retinopathy of Prematurity Animal Model
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
15 mai 2024 08h35 HE
|
ZyVersa Therapeutics
ZyVersa is on track to achieve key development milestones over the next 3 quarters.